Combining targeted therapies significantly boosted survival in kidney cancer study
Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall ...
Oct 28, 2026
0
8









